NITIN KAPOOR

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology WASHINGTON, PA NPI 1013952878

General Payments — all program years on this page

$24,641.81

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 78
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $2,212.22 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $1,937.503
Food and Beverage $274.7215

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $1,220.904
Siemens Medical Solutions USA, Inc. $800.002
Celgene Corporation $153.9110
BeiGene USA, Inc. $24.141
Tempus AI, Inc $13.271

By program year

Program yearAmountRecords
2018 $14.461
2019 $5,174.163
2020 $4,587.606
2021 $5,860.156
2022 $1,272.1115
2023 $5,521.1129
2024 $2,212.2218

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1093694174 Siemens Medical Solutions USA, Inc. $400.00 08/06/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093694176 Siemens Medical Solutions USA, Inc. $400.00 09/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1101093618 Celgene Corporation $22.04 02/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093622 Celgene Corporation $18.87 03/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093626 Celgene Corporation $21.47 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093630 Celgene Corporation $17.36 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093634 Celgene Corporation $23.03 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093638 Celgene Corporation $4.22 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093640 Celgene Corporation $7.99 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093642 Celgene Corporation $15.52 10/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093644 Celgene Corporation $21.94 10/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101093646 Celgene Corporation $1.47 11/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104305302 AstraZeneca Pharmaceuticals LP $1,137.50 02/29/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104443244 AstraZeneca Pharmaceuticals LP $18.34 08/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104761818 AstraZeneca Pharmaceuticals LP $47.01 03/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105802271 AstraZeneca Pharmaceuticals LP $18.05 09/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120864188 BeiGene USA, Inc. $24.14 07/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150167330 Tempus AI, Inc $13.27 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.